On Friday, Immunic Inc (IMUX) stock saw a decline, ending the day at $1.19 which represents a decrease of $-0.02 or -1.65% from the prior close of $1.21. The stock opened at $1.21 and touched a low of ...

Leerink Partners has recently resumed Immunic Inc (IMUX) stock to Outperform rating, as announced on September 9, 2024, according to Finviz. Earlier, on August 27, 2024, B. Riley Securities had ...

Immunic (IMUX) stock fell after the company said it plans to continue its Phase 3 ENSURE program for lead drug IMU-838 in ...

Other Income: $0.4 million for Q2 2024, up from $0.1 million in Q2 2023. Immunic Inc (NASDAQ:IMUX) reported promising preclinical and clinical data for vidofludimus calcium, highlighting its ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...

Given this risk, we thought we'd take a look at whether Immunic (NASDAQ:IMUX) shareholders should be worried about its cash burn. For the purposes of this article, cash burn is the annual rate at ...

Other Income: $0.4 million for Q2 2024, up from $0.1 million in Q2 2023. Immunic Inc (NASDAQ:IMUX) reported promising preclinical and clinical data for vidofludimus calcium, highlighting its ...

Immunic to Participate in Industry, Scientific and Investor Conferences in November 29.10.2024 / 11:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to ...

Other Income: $0.4 million for Q2 2024, up from $0.1 million in Q2 2023. Warning! GuruFocus has detected 2 Warning Signs with IMUX. Release Date: August 08, 2024 For the complete transcript of the ...

Analyst Faisal Khurshid from Leerink Partners reiterated a Buy rating on Immunic (IMUX – Research Report) and keeping the price target at ...

NEW YORK, Oct. 22, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline ...